Apellis Pharmaceuticals Inc (NASDAQ: APLS) is 4.86% higher on its value in year-to-date trading and has touched a low of $24.34 and a high of $73.80 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The APLS stock was last observed hovering at around $33.16 in the last trading session, with the day’s gains setting it 0.3%.
Currently trading at $33.46, the stock is 0.23% and 7.92% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.74 million and changing 0.90% at the moment leaves the stock -12.11% off its SMA200. APLS registered -44.23% loss for a year compared to 6-month loss of -7.67%. The firm has a 50-day simple moving average (SMA 50) of $31.004 and a 200-day simple moving average (SMA200) of $38.068974.
The stock witnessed a -3.38% gain in the last 1 month and extending the period to 3 months gives it a 19.24%, and is 1.53% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.39% over the week and 4.24% over the month.
Apellis Pharmaceuticals Inc (APLS) has around 706 employees, a market worth around $4.20B and $715.22M in sales. Profit margin for the company is -34.97%. Distance from 52-week low is 37.47% and -54.66% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.69%).
The EPS is expected to grow by 62.32% this year.
Apellis Pharmaceuticals Inc (APLS) Top Institutional Holders
379.0 institutions hold shares in Apellis Pharmaceuticals Inc (APLS), with institutional investors hold 114.84% of the company’s shares. The shares outstanding are 122.07M, and float is at 101.46M with Short Float at 19.72%. Institutions hold 98.84% of the Float.
The top institutional shareholder in the company is WELLINGTON MANAGEMENT GROUP LLP with over 16.39 million shares valued at $628.67 million. The investor’s holdings represent 13.2269% of the APLS Shares outstanding. As of 2024-06-30, the second largest holder is ECOR1 CAPITAL, LLC with 11.61 million shares valued at $445.26 million to account for 9.3681 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 11.11 million shares representing 8.9675% and valued at over $426.22 million, while VANGUARD GROUP INC holds 7.9171 of the shares totaling 9.81 million with a market value of $376.29 million.
Apellis Pharmaceuticals Inc (APLS) Insider Activity
The most recent transaction is an insider sale by Eisele Jeffrey, the company’s Chief Development Officer. SEC filings show that Eisele Jeffrey sold 63 shares of the company’s common stock on Dec 23 ’24 at a price of $33.09 per share for a total of $2085.0. Following the sale, the insider now owns 57145.0 shares.
Still, SEC filings show that on Dec 11 ’24, Watson David O. (General Counsel) disposed off 5,000 shares at an average price of $34.23 for $0.17 million. The insider now directly holds 112,721 shares of Apellis Pharmaceuticals Inc (APLS).
